# Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial

> **NCT04003857** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Medipost Co Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Bronchopulmonary Dysplasia
- BPD

## Interventions

- **BIOLOGICAL:** PNEUMOSTEM®
- **BIOLOGICAL:** normal saline

## Key facts

- **NCT ID:** NCT04003857
- **Lead sponsor:** Medipost Co Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-05
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04003857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04003857, "Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04003857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*